ROIX — Response Oncology Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -217.98% | ||
| Return on Equity | -773.14% | ||
| Operating Margin | -48.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 1997 | 1998 | 1999 | 2000 | 2001 | 2002E | 2003E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 101.92 | 128.25 | 135.57 | 130.83 | 118.08 | n/a | n/a | 11.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +227.32 | +29.62 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Response Oncology, Inc. was, prior to the sales of its assets, a comprehensive cancer management company. As of May 20, 2002, the Company had liquidated substantially all of its operating assets and anticipates that the remaining assets will be liquidated and all wind-down activities completed by the end of 2002. Prior to the sale of its assets, the Company provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists; owned the assets of and managed the non-medical aspects of oncology practices; compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee; and conducted outcomes research on behalf of pharmaceutical manufacturers.
Directors
- Last Annual
- December 31st, 2001
- Last Interim
- March 31st, 2002
- Incorporated
- June 26th, 1984
- Public Since
- October 26th, 1995
- No. of Shareholders
- 1,831
- No. of Employees
- 10
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 12,178,701
- Address
- 1805 Moriah Woods Blvd, MEMPHIS, 38117-7121
- Web
- Phone
- +1 9017617000
- Auditors
- KPMG LLP
Similar to ROIX
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
ACI Global
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
FAQ
As of Today at 19:18 UTC, shares in Response Oncology are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Response Oncology last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Response Oncology share price has underperformed the S&P500 Index by -11.77% over the past year.
There is no consensus recommendation for this security.
Response Oncology does not currently pay a dividend.
Response Oncology does not currently pay a dividend.
Response Oncology does not currently pay a dividend.
To buy shares in Response Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Response Oncology had a market capitalisation of .
Here are the trading details for Response Oncology:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ROIX
Based on an overall assessment of its quality, value and momentum Response Oncology is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Response Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -13.79%.
As of the last closing price of $0.00, shares in Response Oncology were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Response Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Response Oncology's management team is headed by:
- Charles Sweet - CEO
- Peter Stark - CFO
- Joames Skinner - DRC